Comparison of Efficacy and Safety Outcomes of Different Doses Schedules of Thalidomide for Treating Moderate-to-Severe β-Thalassemia Patients
Wei-Jia Yang, Lian-dong Shi, Ye Liang, Li-ming Liang, Hao Zhang, Li Wang, Qian Zhou · 2024
Read Comparison of Efficacy and Safety Outcomes of Different Doses Schedules of Thalidomide for Treating Moderate-to-Severe β-Thalassemia Patients by Wei-Jia Yang, Lian-dong Shi, Ye Liang, Li-ming Liang, Hao Zhang, Li Wang, Qian Zhou (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11616116.txt.
Description
Wei-Jia Yang and six co-authors review two years of thalidomide care for people with moderate to severe beta-thalassemia, a blood disorder. The 2024 study followed forty-eight patients on small or medium doses of the drug. The team tracked blood counts, liver and kidney tests, and side effects over the full two years. They also watched what happened when doses were cut for patients who had side effects.
Most patients responded, and blood levels rose in about nine of ten cases. No severe nerve harm and no vein clots appeared, and liver and kidney tests stayed sound. When doses were lowered, gains mostly held for a year. The authors favor small long-term doses for safety.
Catalog record
| CREATOR | Wei-Jia Yang, Lian-dong Shi, Ye Liang, Li-ming Liang, Hao Zhang, Li Wang, Qian Zhou |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |